Company news
X4 Pharmaceuticals, Inc. news in 2020
X4 Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer
December 13, 2020
X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome
December 9, 2020
X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 4, 2020
X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer
November 1, 2020
X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020
October 21, 2020
X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome
October 7, 2020
X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton
September 30, 2020
X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology
September 1, 2020
X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
July 29, 2020
X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020
July 15, 2020
X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020
June 11, 2020
X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer
June 10, 2020
X4 Pharmaceuticals Announces Data from Phase 2 Open-Label Extension Trial of Mavorixafor in WHIM Syndrome as Published in EHA Abstract
May 13, 2020
X4 Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
May 11, 2020
X4 Pharmaceuticals Provides Corporate Update, Including Expected Impact of COVID-19, and Reports First Quarter 2020 Financial Results
May 6, 2020
X4 Pharmaceuticals to Announce First Quarter 2020 Financial Results and Provide Recent Business Highlights on May 7, 2020
April 22, 2020
X4 Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
March 11, 2020
X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020
February 26, 2020
X4 Pharmaceuticals Granted New Composition of Matter Patent for Late-Stage Clinical Candidate Mavorixafor
February 11, 2020